Related Experiment Video
Updated: Jun 27, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
PEDF as an emerging therapeutic candidate for osteosarcoma
Crispin R Dass1, Eugene T H Ek, Peter F M Choong
1Department of Orthopaedics and Surgery, University of Melbourne, St Vincent's Hospital, Melbourne, Australia. crispin.dass@svhm.org.au
Abstract:
Osteosarcoma (OS) is a disease that afflicts teenagers and adolescents in the prime of their lives. In spite of surgery and therapies currently used, there is a 1/3 chance of relapse. As for other cancers, current research is largely devoted to elucidating the molecular basis of the disease, with the anticipation that such research will lead to discovery and development of biological therapies. The major advantage of utilising such therapy is the relative lack of toxicity to normal tissues. One such enterprising candidate molecule, pigment epithelium-derived factor (PEDF), has recently been implicated to be involved in control of OS in orthotopic spontaneously metastasising models of the disease, whether administered as recombinant protein, overexpressed or administered as short peptides derived from the parent molecule. Expression of PEDF is inversely proportional to expression of vascular endothelial growth factor (VEGF) at the growth plate cartilage layer of growing bone in both mice and man. PEDF, originally discovered for its potent antiangiogenic activity, is now established as an anticancer factor with multiple mechanisms at its disposal for tumour inhibition. Current efforts are devoted to develop drug delivery systems, such as controlled release nanoparticles, that can be used to progress this potential drug candidate closer towards clinical trials for OS.
Insights
Pigment epithelium-derived factor (PEDF) shows promise as a novel biological therapy for osteosarcoma (OS), a bone cancer affecting adolescents. Research indicates PEDF inhibits tumor growth and may reduce relapse rates, offering a less toxic treatment option.
Area of Science:
- Oncology
- Molecular Biology
- Biomedical Engineering
Background:
- Osteosarcoma (OS) is a prevalent bone cancer in adolescents with a significant relapse rate despite current treatments.
- Elucidating the molecular basis of OS is crucial for developing targeted biological therapies with reduced toxicity.
- Pigment epithelium-derived factor (PEDF) has emerged as a potential therapeutic agent for OS.
Purpose of the Study:
- To investigate the role of pigment epithelium-derived factor (PEDF) in controlling osteosarcoma (OS) progression.
- To explore PEDF's therapeutic potential as a biological agent against OS.
- To advance PEDF as a drug candidate towards clinical trials for OS treatment.
Main Methods:
- Utilizing orthotopic, spontaneously metastasizing models of osteosarcoma in preclinical studies.
- Administering PEDF as recombinant protein, via overexpression, or as short peptide derivatives.
- Analyzing the inverse relationship between PEDF and vascular endothelial growth factor (VEGF) expression in bone growth plate cartilage.
Main Results:
- PEDF demonstrates tumor inhibition in preclinical OS models.
- PEDF expression is inversely correlated with vascular endothelial growth factor (VEGF) expression in growing bone.
- PEDF exhibits multiple anti-tumor mechanisms beyond its known anti-angiogenic activity.
Conclusions:
- Pigment epithelium-derived factor (PEDF) is a promising biological therapeutic candidate for osteosarcoma.
- PEDF's multifaceted anti-cancer properties warrant further investigation for OS treatment.
- Development of drug delivery systems, like nanoparticles, is key to advancing PEDF towards clinical application for OS.
